Technical Analysis for ARNA - Arena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 48.455 -2.13% -1.06
ARNA closed down 0.34 percent on Tuesday, October 22, 2019, on 51 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Nov 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ARNA trend table...

Date Alert Name Type % Chg
Multiple of Ten Bearish Other -2.13%
Weak + Overbought Other -2.13%
Outside Day Range Expansion -2.13%
Overbought Stochastic Strength -2.13%
Pocket Pivot Bullish Swing Setup -2.47%
Multiple of Ten Bearish Other -2.47%
Weak + Overbought Other -2.47%
Overbought Stochastic Strength -2.47%
NR7 Range Contraction -0.74%
Weak + Overbought Other -0.74%

Older signals for ARNA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company offers BELVIQ, a drug candidate approved by the United States food and drug administration for chronic weight management in adults. It is also involved in the development of APD811, an agonist of the prostacyclin receptor, which is in Phase I clinical trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor that is in Phase I clinical trials for the treatment of thrombotic diseases. In addition, the company's preclinical development products comprise APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; and GPR119 agonists intended for the treatment of type 2 diabetes. Further, it manufactures drug products under a manufacturing services agreement. The company has a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd. for the commercialization of BELVIQ in South Korea. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Chemistry Health Biopharmaceutical Food Pain Diabetes Medication Autoimmune Diseases Pharmacology Pulmonary Arterial Hypertension Metabolic Diseases Treatment Of Autoimmune Diseases Inflammatory Cannabinoids Chronic Weight Management Manufacturing Services Agreement United States Food And Drug Administration
Is ARNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 64.48
52 Week Low 31.97
Average Volume 372,040
200-Day Moving Average 51.2003
50-Day Moving Average 50.5029
20-Day Moving Average 46.9073
10-Day Moving Average 48.0905
Average True Range 1.5542
ADX 28.26
+DI 23.3449
-DI 17.2827
Chandelier Exit (Long, 3 ATRs ) 47.1774
Chandelier Exit (Short, 3 ATRs ) 48.9726
Upper Bollinger Band 50.353
Lower Bollinger Band 43.4616
Percent B (%b) 0.88
BandWidth 14.69153
MACD Line -0.3453
MACD Signal Line -1.0378
MACD Histogram 0.6925
Fundamentals Value
Market Cap 1.94 Billion
Num Shares 39.2 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -66.91
Price-to-Sales 8.96
Price-to-Book 12.74
PEG Ratio 0.45
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 51.55
Resistance 3 (R3) 51.57 50.91 51.21
Resistance 2 (R2) 50.91 50.39 50.90 51.10
Resistance 1 (R1) 50.21 50.07 49.88 50.19 50.98
Pivot Point 49.55 49.55 49.39 49.54 49.55
Support 1 (S1) 48.85 49.03 48.52 48.83 48.04
Support 2 (S2) 48.19 48.71 48.18 47.92
Support 3 (S3) 47.49 48.19 47.81
Support 4 (S4) 47.47